Gujarat Kidney And Super Speciality profitability ratios

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026

Returns
	6.1%	6.1%
	5.7%	5.7%
	8.2%	8.2%
	6.8%	6.8%
Margins
	26.4%	32.9%
	27.1%	27.1%
	20.5%	25.9%
	16.6%	20.5%
	15.7%	18.9%
	−17.9%	−17.9%
Additional
	19.2%	20.8%
	6.1%	6.1%

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

GKSL₹171.87

Gujarat Kidney And Super Speciality Limited

· Pharma & Health

₹ CrorePeersGPTHEALTH SHALBY INDRAMEDCO LOTUSEYE ARTEMISMED DRAGARWQ KMCSHIL KOVAIMcap ₹1,355 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY26 31/03/2026	Last 12M 30/06/2026
Returns
Return on Common Equity	6.14	6.14
Return on Assets	5.65	5.65
Return on Capital Employed	8.24	8.24
Return on Invested Capital	6.85	6.76
Margins
EBITDA Margin	32.85	26.42
Operating Margin	27.12	27.12
Pretax Margin	25.89	20.50
Net Income Margin	20.50	16.56
Net Income to Common Margin	18.90	15.67
FCF Margin	-17.89	-17.89
Additional
Effective Tax Rate	20.83	19.22
Sustainable Growth Rate	6.14	6.14

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.